News Releases

Aug 10, 2021
Biodesix Announces Second Quarter 2021 Results and Highlights
Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acceleration of the Launch of the 72-hour liquid NGS Test to Early First Quarter 2022 Conference Call and Webcast Today at 4:30 p.m.
Aug 02, 2021
Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference
BOULDER, Colo. --(BUSINESS WIRE)--Aug. 2, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at the Canaccord Genuity 41st Annual Growth Conference
Jul 27, 2021
Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
BOULDER, Colo. --(BUSINESS WIRE)--Jul. 27, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday,
Jun 04, 2021
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
Biodesix intends to make its databank and linked data accessible to research and biopharma partners BOULDER, Colo. & SAN FRANCISCO --(BUSINESS WIRE)--Jun. 4, 2021-- Biodesix, Inc.  (Nasdaq: BDSX),   a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant,
Displaying 1 - 10 of 32